This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    nor-202
Previous Study | Return to List | Next Study

Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine in Children

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT02153112
First received: May 29, 2014
Last updated: July 27, 2017
Last verified: July 2017
  Purpose
The purpose of this study is to select the optimal formulation of the norovirus vaccine from different concentrations of virus-like particles (VLP) combined with aluminum hydroxide for further development in children.

Condition Intervention Phase
Norovirus Biological: GI.1/GII.4 (15/15) Biological: GI.1/GII.4 (15/50) Biological: GI.1/GII.4 (50/50) Biological: GI.1/GII.4 (50/150) Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase II, Randomized, Double-Blind, Dosage, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine Combined With Aluminum Hydroxide Adjuvant in Children, Toddlers, and Infants

Resource links provided by NLM:


Further study details as provided by Takeda:

Primary Outcome Measures:
  • Percentage of Participants with a Seroresponse (Pan-Ig ELISA) [ Time Frame: Cohort 1: Day 57; Cohort 2: Day 140 ]
    Seroresponse defined as 4-fold rise or greater at Day 57 (Cohort 1) and Day 140 (Cohort 2) in serum anti-norovirus antibody titers for both GI.1 virus-Like particle (VLP) and GII.4 VLP as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).

  • Percentage of Participants with Solicited Local Adverse Events (AEs) at Injection Site [ Time Frame: Days 1 through 7 after each vaccination ]
    Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination.

  • Percentage of Participants with Solicited Systemic Adverse Events (AEs) [ Time Frame: Through Day 7 after each vaccination ]
    Systemic AEs are defined as headache, fatigue, myalgia, arthralgia, vomiting (number per day/intensity), and diarrhea (number per day/consistency) for children aged 4 to <9 years; and irritability/fussiness, drowsiness, loss of appetite, vomiting (number per day/intensity), and diarrhea (number per day/consistency) for children aged 6 weeks to <4 years on the day of vaccination and daily through Day 7 after each vaccination.

  • Body Temperature Through Day 7 after each Vaccination [ Time Frame: Post-vaccination approximately 30 minutes and 6 hours later, then daily through Day 7 ]
    Body temperature measurement will be performed using the thermometer provided by the site through Day 7 after each vaccination. The highest body temperature observed each day will be recorded on the Diary Card.

  • Percentage of Participants with Unsolicited Adverse Events (AEs) [ Time Frame: For 28 days after each vaccination ]
    Unsolicited AEs are any local or systemic AEs, as defined by this study, that are not solicited.

  • Percentage of Participants with Serious Adverse Events (SAEs) [ Time Frame: Cohort 1: Day 1 up to Day 210; Cohort 2: Day 1 up to Day 293 ]
    A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.


Secondary Outcome Measures:
  • Percentage of Participants with a Seroresponse for GI.1 Virus-Like Particle (VLP) (Pan-Ig ELISA) [ Time Frame: Cohort 1: Day 57; Cohort 2: Day 140 ]
    Seroresponse defined as 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-Like particle (VLP) as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).

  • Percentage of Participants with a Seroresponse for GII.4 Virus-Like Particle (VLP) (Pan-Ig ELISA) [ Time Frame: Cohort 1: Day 57; Cohort 2: Day 140 ]
    Seroresponse defined as 4-fold rise or greater in serum anti-norovirus antibody titers for GII.4 virus-Like particle (VLP) as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).

  • Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (Pan-Ig ELISA) [ Time Frame: Cohort 1: Day 57; Cohort 2: Day 140 ]
    Geometric mean titer (GMT) of anti-norovirus GI.1 VLP antibody titers as measured by pan-Ig ELISA.

  • Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (Pan-Ig ELISA) [ Time Frame: Cohort 1: Day 57; Cohort 2: Day 140 ]
    Geometric mean titer (GMT) of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA.

  • Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (Pan-Ig ELISA) [ Time Frame: Cohort 1: Day 57; Cohort 2: Day 140 ]
    Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by pan-Ig ELISA.

  • Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (Pan-Ig ELISA) [ Time Frame: Cohort 1: Day 57; Cohort 2: Day 140 ]
    Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA.

  • Percentage of Participants with a 4-Fold Rise or Greater in Serum Antibody Titers for GI.1 VLP and GII.4 VLP (HBGA) [ Time Frame: Cohort 1: Day 57; Cohort 2: Day 140 ]
    Percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 VLP and GII.4 VLP as measured by histoblood group antigen (HBGA) binding assay.

  • Percentage of Participants with a 4-Fold Rise or Greater in Serum GI.1 VLP Antibody Titers (HBGA) [ Time Frame: Cohort 1: Day 57; Cohort 2: Day 140 ]
    The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-like particle (VLP) as measured by HBGA binding assay.

  • Percentage of Participants with a 4-Fold Rise or Greater in Serum GII.4 VLP Antibody Titers (HBGA) [ Time Frame: Cohort 1: Day 57; Cohort 2: Day 140 ]
    The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GII.4 virus-like particle (VLP) as measured by HBGA binding assay.

  • Blocking Titers 50 (BT50) of Anti-Norovirus GI.1 VLP Antibody Titers (HBGA) [ Time Frame: Cohort 1: Day 57; Cohort 2: Day 140 ]
    Blocking titers 50 (BT50) of anti-norovirus GI.1 VLP antibody titers as measured by HBGA binding assay.

  • Blocking Titers 50 (BT50) of Anti-Norovirus GII.4 VLP Antibody Titers (HBGA) [ Time Frame: Cohort 1: Day 57; Cohort 2: Day 140 ]
    Blocking titers 50 (BT50) of anti-norovirus GII.4 VLP antibody titers as measured by HBGA binding assay.

  • Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (HBGA) [ Time Frame: Cohort 1: Day 57; Cohort 2: Day 140 ]
    Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by HBGA binding assay.

  • Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (HBGA) [ Time Frame: Cohort 1: Day 57; Cohort 2: Day 140 ]
    Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by HBGA binding assay.

  • Percentage of Participants with Any Adverse Event (AE) Leading to Withdrawal from the Study [ Time Frame: Cohort 1: Day 1 up to Day 210; Cohort 2: Day 1 up to Day 293 ]
    Withdrawal due to an AE will occur if the participant experiences an AE that requires early termination because continued participation imposes an unacceptable risk to the participant's health or the participant is unwilling to continue because of the AE.


Estimated Enrollment: 840
Actual Study Start Date: June 23, 2015
Estimated Study Completion Date: November 15, 2018
Estimated Primary Completion Date: November 15, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort 1, Group 1: 1 Dose
Children 4 to <9 years of age will receive one dose of 1 of the 4 formulations of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM), on Day 1, followed by placebo saline solution, IM, on Day 29.
Biological: GI.1/GII.4 (15/15)
Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (15/50)
Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (50/50)
Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (50/150)
Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Drug: Placebo
Placebo saline solution
Experimental: Cohort 1, Group 1: 2 Doses
Children 4 to <9 years of age will receive 2 doses of 1 of the 4 formulations of the norovirus bivalent VLP vaccine, intramuscularly (IM), on Day 1 and Day 29.
Biological: GI.1/GII.4 (15/15)
Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (15/50)
Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (50/50)
Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (50/150)
Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Experimental: Cohort 1, Group 2: 1 Dose
Children 1 to <4 years of age will receive one dose of 1 of the 4 formulations of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM), on Day 1, followed by placebo saline solution, IM, on Day 29.
Biological: GI.1/GII.4 (15/15)
Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (15/50)
Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (50/50)
Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (50/150)
Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Drug: Placebo
Placebo saline solution
Experimental: Cohort 1, Group 2: 2 Doses
Children 1 to <4 years of age will receive 2 doses of 1 of the 4 formulations of the norovirus bivalent VLP vaccine, intramuscularly (IM), on Day 1 and Day 29.
Biological: GI.1/GII.4 (15/15)
Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (15/50)
Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (50/50)
Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (50/150)
Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Experimental: Cohort 1, Group 2a: 1 Dose
Children 1 to <4 years of age will receive one dose of 1 of the 4 formulations of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM), on Day 1, followed by placebo saline solution, IM, on Day 29.
Biological: GI.1/GII.4 (15/15)
Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (15/50)
Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (50/50)
Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (50/150)
Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Drug: Placebo
Placebo saline solution
Experimental: Cohort 1, Group 2a: 2 Doses
Children 1 to <4 years of age will receive 2 doses of 1 of the 4 formulations of the norovirus bivalent VLP vaccine, intramuscularly (IM), on Day 1 and Day 29.
Biological: GI.1/GII.4 (15/15)
Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (15/50)
Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (50/50)
Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (50/150)
Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Experimental: Cohort 1, Group 3: 1 Dose
Toddlers 6 months to <1 year of age will receive one dose of 1 of the 4 formulations of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM), on Day 1, followed by placebo saline solution, IM, on Day 29.
Biological: GI.1/GII.4 (15/15)
Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (15/50)
Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (50/50)
Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (50/150)
Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Drug: Placebo
Placebo saline solution
Experimental: Cohort 1, Group 3: 2 Doses
Toddlers 6 months to <1 year of age will receive 2 doses of 1 of the 4 formulations of the norovirus bivalent VLP vaccine, intramuscularly (IM), on Day 1 and Day 29.
Biological: GI.1/GII.4 (15/15)
Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (15/50)
Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (50/50)
Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (50/150)
Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Experimental: Cohort 2, Group 4: 2 Doses
Infants 6 weeks to <6 months of age will receive 2 doses of 1 of the 4 formulations of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM), on Days 1 and 56, followed by placebo saline solution, IM, on Day 112.
Biological: GI.1/GII.4 (15/15)
Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (15/50)
Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (50/50)
Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (50/150)
Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Drug: Placebo
Placebo saline solution
Experimental: Cohort 2, Group 4: 3 Doses
Infants 6 weeks to <6 months of age will receive 3 doses of 1 of the 4 formulations of the norovirus bivalent VLP vaccine, intramuscularly (IM), on Days 1, 56 and 112.
Biological: GI.1/GII.4 (15/15)
Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (15/50)
Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (50/50)
Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Biological: GI.1/GII.4 (50/150)
Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection

Detailed Description:

The vaccine being tested in this study is called norovirus GI.1/GII.4 bivalent virus-like particle (VLP) vaccine with aluminum hydroxide. The norovirus vaccine is being tested to assess different formulations of the vaccine that will then be further developed. This study will look at the number of antibodies to norovirus formed in children, toddlers and infants who are administered different formulations of the norovirus vaccine.

The study will enroll approximately 840 participants. Participants will be randomly assigned (by chance) to one of ten treatment groups—which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need).

All participants in Cohort 1 will be vaccinated on Day 1 and Day 29 of the study, and all participants in Cohort 2 will be vaccinated on Day 1, Day 56, and Day 112. All treatment groups in Cohort 1 will receive either one dose of the norovirus vaccine, or two doses. One treatment group in Cohort 2 will receive 2 doses of the norovirus vaccine, and the other group will receive 3. In order to keep the treatment undisclosed to the participant and the doctor in Cohort 1, those randomized to the one-dose groups will receive the norovirus vaccine on Day 1, followed by a dose of placebo vaccine on Day 29. In order to keep the treatment arms undisclosed to the participant and the doctor in Cohort 2, those randomized to the two-dose groups will receive the norovirus vaccine on Day 1 and Day 56, followed by a dose of placebo vaccine on Day 112. Placebo vaccine is saline solution. Participants will be asked to record any symptoms that may be related to the vaccine or the injection site in a diary card for 7 days after each vaccination.

This multi-center trial will be conducted in Finland, Panama, and Colombia. The overall time to participate in this study is up to 210 days for participants in Cohort 1 and up to 293 Days for participants in Cohort 2. Participants in Cohort 1 will make 6 visits to the clinic, and participants in Cohort 2 will make 10 visits to the clinic.

  Eligibility

Ages Eligible for Study:   6 Weeks to 8 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male and female participants aged between 6 weeks and less than 9 years at the time of enrollment.
  2. Are in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs) and clinical judgment of the investigator.
  3. Participants legally authorized representative (LAR) signs and dates a written, informed consent form (ICF) and any required privacy authorization prior to the initiation of any trial procedures, after the nature of the trial has been explained according to local regulatory requirements. An assent will also be obtained according to age-appropriate country-specific regulations.
  4. Participants who can comply with trial procedures and are available for the duration of the trial.

Exclusion Criteria:

  1. Participants with a clinically significant active infection (as assessed by the investigator) or body temperature 38.0°C (100.4°F) or higher within 3 days of the intended date of vaccination.
  2. Have received antipyretic/analgesic medications within 24 hours prior to the intended vaccine administration.
  3. Known hypersensitivity or allergy to investigational vaccine (including excipients of the investigational vaccines).
  4. Participants with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the ability to participate in the trial.
  5. Has a history of any progressive or severe neurologic disorder, seizure disorder, or neuroinflammatory disease (eg, Guillain-Barré syndrome).
  6. Known or suspected impairment/alteration of immune function, including the following:

    1. Children <18 months of age with history of repeated episodes of acute otitis media (AOM) in the first 6 months of life (AOM defined as a bulging tympanic membrane) and not to be confused with otitis media with effusion (OME).
    2. Chronic use of oral steroids (equivalent to 20 mg/day prednisone for ≥12 weeks/≥2 mg/kg body weight/day for ≥2 weeks) within 60 days prior to Day 1 (use of inhaled, intranasal, or topical corticosteroids is allowed).
    3. Receipt of parenteral steroids (equivalent to 20 mg/day prednisone ≥12 weeks/≥2 mg/kg body weight/day for ≥2 weeks) within 60 days prior to Day 1.
    4. Receipt of immunostimulants within 60 days prior to Day 1.
    5. Receipt of parenteral, epidural, or intra-articular immunoglobulin preparation, blood products, and/or plasma derivatives within 3 months prior to Day 1 or planned during the full length of the trial.
    6. Receipt of immunosuppressive therapy within 6 months prior to Day 1.
    7. Human immunodeficiency virus (HIV) infection or HIV-related disease.
    8. Chronic Hepatitis B or C infection.
    9. Heritable immunodeficiency.
  7. Abnormalities of splenic or thymic function.
  8. Has a known bleeding diathesis or any condition that may be associated with a prolonged bleeding time.
  9. Has any serious chronic or progressive disease according to judgment of the investigator (e.g., neoplasm, insulin dependent diabetes, cardiac, renal, or hepatic disease).
  10. Is participating in any clinical trial with another investigational product 30 days prior to first trial visit or intent to participate in another clinical trial at any time during the conduct of this trial.
  11. Has received any other vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrollment in this trial.
  12. Are first degree relatives of individuals involved in trial conduct.
  13. Has a history of autoimmune disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02153112

Locations
Colombia
Centro de Estudios em Infectologia Pediatrica SAS
Cali, Colombia
Finland
Espoon Rokotetutkimusklinikka
Espoo, Finland
Etela-Helsingin Rokotetutkimusklinikka
Helsinki, Finland
Ita-Helsingin Rokotetutkimusklinikka
Helsinki, Finland
Jarvenpaan Rokotetutkimusklinikka
Jarvenpaan, Finland
Oulun Rokotetutkimusklinikka
Oulu, Finland
Porin Rokotetutkimusklinikka
Pori, Finland
Seinajoen Rokotetutkimusklinikka
Seinajoki, Finland
Tampere Vaccine Research Clinic
Tampere, Finland
Turun Rokotetutkimusklinikka
Turku, Finland
Panama
CEVAXIN Plaza Carolina - Ciudad de Panama
Ciudad de Panama, Panama
CEVAXIN
Panama, Panama
Sponsors and Collaborators
Takeda
Investigators
Study Director: Medical Director Clinical Science Takeda
  More Information

Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT02153112     History of Changes
Other Study ID Numbers: NOR-202
2014-000778-20 ( EudraCT Number )
U1111-1154-9733 ( Other Identifier: World Health Organization )
Study First Received: May 29, 2014
Last Updated: July 27, 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Takeda:
Drug therapy

Additional relevant MeSH terms:
Vaccines
Aluminum Hydroxide
Immunologic Factors
Physiological Effects of Drugs
Adjuvants, Immunologic
Antacids
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Agents

ClinicalTrials.gov processed this record on August 18, 2017